Ticagrelor vs. Prasugrel Effects on Infarct Size

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 29, 2016

Primary Completion Date

August 31, 2017

Study Completion Date

November 30, 2017

Conditions
Cardiovascular Disease
Interventions
DRUG

ticagrelor

A platelet aggregation inhibitor

DRUG

prasugrel

a thienopyridine class inhibitor of platelet activation and aggregation

DRUG

Placebo

placebo

Trial Locations (3)

77030

Baylor-St. Lukes Medical Center, Houston

Houston Methodist Hospital, Houston

Memorial Hermann Hospital, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Yochai Birnbaum

OTHER